Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 11:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 612 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: UC - Ulcerative Colitis Clear all
Completed Phase 2 Interventional

Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis

NCT01461317
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Etrolizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
5
States / cities
La Jolla, California • Atlanta, Georgia • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 24, 2026, 11:50 AM EDT
Completed Not applicable Interventional

Nasal Calcitonin in the Treatment of Bone Mineral Loss in Children and Adolescents With Inflammatory Bowel Disease

NCT00114803
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Calcitonin nasal spray (salmon)
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 22 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 5, 2007 · Synced Oct 24, 2026, 11:50 AM EDT
Completed Phase 2 Interventional

A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis

NCT01959282
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Placebo, JNJ-54781532 25 mg once daily, JNJ-54781532 75 mg once daily, JNJ-54781532 150 mg once daily, JNJ-54781532 75 mg twice daily
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
15
States / cities
La Jolla, California • Thornton, Colorado • Ann Arbor, Michigan + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2019 · Synced Oct 24, 2026, 11:50 AM EDT
Not listed No phase listed Observational

Prospective Multicenter Trial to Determine the Efficacy and Outcome of the UCRI Biomarker Panel and Algorithm to Detect Mucosal Healing in Moderate to Severe Ulcerative Colitis Patients.

NCT04897282
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
UCRI
Diagnostic Test
Lead sponsor
Glycominds, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 24, 2026, 11:50 AM EDT
Completed No phase listed Observational

A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients

NCT00207688
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Infliximab 5 mg/kg, Infliximab 10 mg/kg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
44
States / cities
Scottsdale, Arizona • Anaheim, California • Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Oct 24, 2026, 11:50 AM EDT
Not listed Phase 1 Interventional

A Phase 1b Study to Evaluate APL-1401 in Patients With Moderately to Severely Active Ulcerative Colitis

NCT05743010
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
APL-1401, Placebo
Drug
Lead sponsor
Jiangsu Yahong Meditech Co., Ltd aka Asieris
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Corona, California • Tampa, Florida • Marrero, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 24, 2026, 11:50 AM EDT
Enrolling by invitation No phase listed Observational

Improving the Quality of Care for Adults With Inflammatory Bowel Disease

NCT02791854
View directory record Official record
Conditions
Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Diseases
Interventions
Not listed
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2030
U.S. locations
29
States / cities
Los Angeles, California • Newport Beach, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Oct 24, 2026, 11:50 AM EDT
Completed Phase 3 Interventional

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

NCT05784246
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mirikizumab IV, Mirikizumab SC
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
2 Years to 17 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
San Francisco, California • Atlanta, Georgia • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 24, 2026, 11:50 AM EDT
Terminated Phase 3 Interventional Results available

The Safety and Tolerability of Budesonide Foam in Participants With Active Ulcerative Proctitis or Proctosigmoiditis

NCT01349673
View directory record Official record
Conditions
Proctitis, Proctosigmoiditis
Interventions
Budesonide Foam
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 24, 2026, 11:50 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis

NCT01470612
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
944 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
75
States / cities
Mobile, Alabama • Tucson, Arizona • La Jolla, California + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2021 · Synced Oct 24, 2026, 11:50 AM EDT
Recruiting No phase listed Observational

A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring

NCT05953402
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Female only
Enrollment
1,182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 24, 2026, 11:50 AM EDT
Completed No phase listed Observational

The Impact of Anti-TNF Exposure on Vedolizumab Effectiveness

NCT02423512
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 24, 2026, 11:50 AM EDT
Recruiting Phase 2 Interventional

Selenium Supplementation in Moderate-Severely Active Ulcerative Colitis Patients Treated With Advanced Therapies

NCT07427017
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
Selenium supplementation, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 85 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 24, 2026, 11:50 AM EDT
Not listed Phase 2 Interventional

Efficacy and Tolerability Study of Natura-Alpha in the Treatment of Patients With Active Ulcerative Colitis

NCT01216280
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
placebo capsule, 10 mg Natura-alpha capsule and 10 mg placebo capsule, 2 x 10 mg Natura-alpha capsules
Drug
Lead sponsor
Natrogen Therapeutics International, Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
10
States / cities
Anaheim, California • Chevy Chase, Maryland • Kansas City, Missouri + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Oct 24, 2026, 11:50 AM EDT
Not yet recruiting Not applicable Interventional

Impact of a Human Origin Heat Inactivated Probiotic-Lactobacillus Paracasei D3.5 (LpD3.5) as Dietary Supplement on Gut Mucin and Intestinal Permeability in Adults With IBD

NCT07017959
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
LpD3.5 supplementation., Placebo
Dietary Supplement
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 24, 2026, 11:50 AM EDT
Terminated Phase 1 Interventional Results available

Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC)

NCT03943550
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
RO7049665, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Oct 24, 2026, 11:50 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety Study of GED-0507-34-Levo for Treatment of UC

NCT02808390
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
GED-0507-34-Levo 80 mg, GED-0507-34-Levo 160 mg, Placebo
Drug
Lead sponsor
PPM Services S.A.
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
San Diego, California • Maitland, Florida • New Port Richey, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Oct 24, 2026, 11:50 AM EDT
Terminated Phase 3 Interventional Results available

Vedolizumab Monotherapy Vs Combination Therapy With Tacrolimus in UC

NCT02954159
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Tacrolimus, Vedolizumab, Placebo
Drug · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Oct 24, 2026, 11:50 AM EDT
Completed Phase 1 Interventional Results available

Low Dose IL-2 for Ulcerative Colitis

NCT02200445
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Interleukin-2 (aldesleukin).
Drug
Lead sponsor
Scott B. Snapper, MD PHD
Other
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 24, 2026, 11:50 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

NCT04254783
View directory record Official record
Conditions
Ulcerative Colitis (UC), Crohn's Disease
Interventions
Risankizumab, Cytochrome P450 (CYP) Substrates
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
Coronado, California • DeLand, Florida • Margate, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 24, 2026, 11:50 AM EDT
Not listed Phase 3 Interventional

A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis

NCT05181137
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
SHR0302, Placebo
Drug
Lead sponsor
Reistone Biopharma Company Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
23
States / cities
Dothan, Alabama • Lancaster, California • New Haven, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Oct 24, 2026, 11:50 AM EDT
Completed Phase 1 Interventional

Mind/Body Medicine and IBD Flare-Up

NCT00568256
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mind/Body Courses
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Oct 24, 2026, 11:50 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis

NCT02914522
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Filgotinib, PTM filgotinib
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
61
States / cities
Dothan, Alabama • Scottsdale, Arizona • Long Beach, California + 53 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Oct 24, 2026, 11:50 AM EDT
Completed Phase 3 Interventional Results available

Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study

NCT00486031
View directory record Official record
Conditions
Inflammatory Bowel Disease, Ulcerative Colitis
Interventions
Balsalazide Disodium
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
95
States / cities
Birmingham, Alabama • Tempe, Arizona • Fayetteville, Arkansas + 82 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2019 · Synced Oct 24, 2026, 11:50 AM EDT